Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes
Nicholas A. Marston, Erin A. Bohula, Ajay Bhatia, Gaetano M. De Ferrari et autres
19 citationsJAMA
Staffan Salmonsson
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
6Publications signalées
5731Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Diabetes Treatment and ManagementLipoproteins and Cardiovascular HealthBariatric Surgery and OutcomesCoronary Interventions and DiagnosticsHeart Failure Treatment and Management
Publications récentes
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study
Kausik K. Ray, Carlos Aguíar, Marcello Arca, Derek Connolly et autres
76 citationsEuropean Journal of Preventive Cardiology
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Díaz et autres
644 citationsThe Lancet
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Rafael Díaz et autres
3152 citationsThe Lancet
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, Ralph B. D’Agostino et autres
1840 citationsThe Lancet
An evaluation of the national CDD program in Zambia.
Jacqui Brown, Staffan Salmonsson, T Leifert, P Spain et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.